[1] |
Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis⁃like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis[J]. Clin Rheumatol, 2009,28(8):979⁃984. doi: 10.1007/s10067⁃009⁃1152⁃9.
|
[2] |
Sun Y, Liu Y, Yan B, et al. Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients[J]. Rheumatol Int, 2013,33(5):1295⁃1302. doi: 10.1007/s00296⁃012⁃2545⁃7.
|
[3] |
Udkoff J, Cohen PR. Amyopathic dermatomyositis: a concise review of clinical manifestations and associated malignancies[J]. Am J Clin Dermatol, 2016,17(5):509⁃518. doi: 10.1007/s40257⁃016⁃0199⁃z.
|
[4] |
Wang J, Guo G, Chen G, et al. Meta⁃analysis of the association of dermatomyositis and polymyositis with cancer[J]. Br J Dermatol, 2013,169(4):838⁃847. doi: 10.1111/bjd.12564.
|
[5] |
Marinov GK. On the design and prospects of direct RNA sequencing[J]. Brief Funct Genomics, 2017,16(6):326⁃335. doi: 10.1093/bfgp/elw043.
|
[6] |
Zolotarenko A, Chekalin E, Mehta R, et al. Identification of transcriptional regulators of psoriasis from RNA⁃Seq experiments[J]. Methods Mol Biol, 2017,1613:355⁃370. doi: 10.1007/978⁃1⁃4939⁃7027⁃8_14.
|
[7] |
Rai R, Chauhan SK, Singh VV, et al. RNA⁃seq analysis reveals unique transcriptome signatures in systemic lupus erythematosus patients with distinct autoantibody specificities[J/OL]. PLoS One, 2016,11(11):e0166312. [2016⁃11⁃07]. doi: 10.1371/ journal.pone.0166312.
|
[8] |
Li J, Li Q, Chen L, et al. Expression profile of circular RNAs in infantile hemangioma detected by RNA⁃Seq[J/OL]. Medicine (Baltimore), 2018,97(21):e10882. [2019⁃10⁃10]. doi: 10.1097/MD. 0000000000010882.
|
[9] |
García⁃Martín A, Garrido⁃Rodríguez M, Navarrete C, et al. Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis[J]. Biochem Pharmacol, 2019,163:321⁃334. doi: 10.1016/j.bcp.2019.02.029.
|
[10] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975,292(7):344⁃347. doi: 10. 1056/NEJM197502132920706.
|
[11] |
Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects[J]. Dermatol Clin, 2002,20(3):387⁃408.
|
[12] |
Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis[J]. Muscle Nerve, 2015,51(5):638⁃656. doi: 10.1002/mus.24566.
|
[13] |
Ebrahimiyan H, Rezaei N, Vojdanian M, et al. microRNA involvement in the regulation of survivin in peripheral blood mononuclear cells from rheumatoid arthritis patients[J]. Int J Rheum Dis, 2019,22(6):1107⁃1114. doi: 10.1111/1756⁃185X. 13520.
|
[14] |
Bilgic H, Ytterberg SR, Amin S, et al. Interleukin⁃6 and type I interferon⁃regulated genes and chemokines mark disease activity in dermatomyositis[J]. Arthritis Rheum, 2009,60(11):3436⁃3446. doi: 10.1002/art.24936.
|
[15] |
Rongvaux A. Innate immunity and tolerance toward mitochondria[J]. Mitochondrion, 2018,41:14⁃20. doi: 10.1016/j.mito.2017.10. 007.
|
[16] |
钟勇, 柴克霞. 自噬相关蛋白mTOR、LC3⁃Ⅱ及HIF⁃1α 与PM/DM的相关性[J]. 中国高原医学与生物学杂志, 2018,39(4):242⁃246. doi: 10.13452/j.cnki.jqmc.2018.04.005.
|
[17] |
Mamyrova G, Rider LG, Ehrlich A, et al. Environmental factors associated with disease flare in juvenile and adult dermatomyositis[J]. Rheumatology (Oxford), 2017,56(8):1342⁃1347. doi: 10.1093/rheumatology/kex162.
|
[18] |
Sugiyama Y, Yoshimi R, Tamura M, et al. The predictive prognostic factors for polymyositis/dermatomyositis⁃associated interstitial lung disease[J]. Arthritis Res Ther, 2018,20(1):7. doi: 10.1186/s13075⁃017⁃1506⁃7.
|
[19] |
Bador KM, Intan S, Hussin S, et al. Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus[J]. Lupus, 2012,21(11):1172⁃1177. doi: 10.1177/0961203312450085.
|
[20] |
Thrastardottir T, Love TJ. Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review[J]. Rheumatol Int, 2018,38(8):1385⁃1397. doi: 10.1007/s00296⁃017⁃3873⁃4.
|
[21] |
Lu X, Tang Q, Lindh M, et al. The host defense peptide LL⁃37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis[J]. J Autoimmun, 2017,78:46⁃56. doi: 10.1016/j.jaut.2016.12.003.
|
[22] |
Cao H, Xia Q, Pan M, et al. Gottron papules and Gottron sign with ulceration: a distinctive cutaneous feature in a subset of patients with classic dermatomyositis and clinically amyopathic dermatomyositis[J]. J Rheumatol, 2016,43(9):1735⁃1742. doi: 10.3899/jrheum.160024.
|
[23] |
Arshanapalli A, Shah M, Veerula V, et al. The role of type I interferons and other cytokines in dermatomyositis[J]. Cytokine, 2015,73(2):319⁃325. doi: 10.1016/j.cyto.2014.11.026.
|
[24] |
Dourmishev LA, Hristova MH, Kamenarska ZG, et al. Genetically determined TNF⁃α secretion influences the development of dermatomyositis and systemic lupus erythematosus[J]. Folia Med (Plovdiv), 2018,60(2):216⁃220. doi: 10.1515/folmed⁃2017⁃0084.
|
[25] |
Silva MG, Oba⁃Shinjo SM, Marie S, et al. Serum interleukin⁃17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis[J]. Clin Exp Rheumatol, 2019,37(4):656⁃662.
|
[26] |
Chen M, Quan C, Diao L, et al. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis[J]. Br J Dermatol, 2018,179(6):1334⁃1341. doi: 10.1111/bjd.17079.
|
[27] |
尤旭杰, 刘升云. 多发性肌炎/皮肌炎与恶性肿瘤[J]. 肿瘤基础与临床, 2017,30(2):170⁃172. doi: 10.3969/j.issn.1673⁃5412. 2017.02.029.
|
[28] |
Xu Q, Chiao P, Sun Y. Amphiregulin in cancer: new insights for translational medicine[J]. Trends Cancer, 2016,2(3):111⁃113. doi: 10.1016/j.trecan.2016.02.002.
|
[29] |
Cerezo⁃Wallis D, Soengas MS. Understanding tumor⁃antigen presentation in the new era of cancer immunotherapy[J]. Curr Pharm Des, 2016,22(41):6234⁃6250. doi: 10.2174/138161282 2666160826111041.
|
[30] |
Malmberg KJ, Carlsten M, Björklund A, et al. Natural killer cell⁃mediated immunosurveillance of human cancer[J]. Semin Immunol, 2017,31:20⁃29. doi: 10.1016/j.smim.2017.08.002.
|